D-TACE

DRUG3 trials

Sponsors

Xiangya Hospital of Central South University, Wen Li, Hua Li

Conditions

LiverNeoplasm MetastasisNeuroendocrine TumorsUnresectable Hepatocellular CarcinomaUnresectable Intrahepatic Cholangiocarcinoma

Phase 1

DEBOXA for Inoperable NET Liver Metastases

Xiangya Hospital of Central South UniversityLiver, Neoplasm Metastasis, Neuroendocrine Tumors

Start: 2018-07-01End: 2021-12-31Target: 60Updated: 2020-08-20

Phase 2

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Wen LiUnresectable Hepatocellular Carcinoma

Start: 2021-01-01End: 2024-01-01Target: 60Updated: 2022-10-17

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

RecruitingNCT05738057

Hua LiUnresectable Intrahepatic Cholangiocarcinoma

Start: 2023-06-30End: 2026-03-01Target: 22Updated: 2023-11-29